New combo therapy aims to boost survival in kids with aggressive lymphoma
NCT ID NCT07168980
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study tests whether giving intensive chemotherapy along with early and strong doses of the targeted drug rituximab can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive this combination, and researchers will compare their event-free survival and overall survival to results from an earlier study. The goal is to find a more effective treatment for this serious cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, Shanghai Municipality, 201315, China
Conditions
Explore the condition pages connected to this study.